EMA has issued the recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2022.
Manufacturers of egg-based or live attenuated quadrivalent vaccines for the 2022-2023 season should include these four virus strains:
- an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
- an A/Darwin/9/2021 (H3N2)-like virus;
- a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
- a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Manufacturers of cell-based quadrivalent vaccines for the 2022-2023 season should include these four virus strains…